UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 10, 2021
________________
NOVO NORDISK A/S
(Exact name of Registrant as
specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark
whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
|
Form 20-F
[X] |
Form 40-F
[ ] |
Indicate by check mark
whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked,
indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by
board members, executives and associated persons on 8 February
2021
Bagsværd, Denmark,
10 February 2021 — This document discloses the data of
the transaction(s) made in Novo Nordisk shares by the company’s
board members, executives and their associated persons in
accordance with Article 19 of Regulation No. 596/2014 on market
abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued by
Novo Nordisk.
Novo Nordisk may, when recruiting employees, provide a recruitment
package in the form of cash payment or share incentive programme.
The reporting below reflects shares granted to Ms Monique Carter as
part of a recruitment arrangement entered into prior to her
appointment as executive.
| 1 |
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a) |
Name of the Board
member/Executive/Associated Person |
Monique Carter |
|
2 |
Reason
for the notification |
|
a) |
Position/status |
Executive vice president, People
& Organisation |
|
b) |
Initial
notification/Amendment |
Initial notification |
|
3 |
Details
of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
Page 2 of 3
| 4 |
Details
of the transaction(s) |
|
a) |
Description of the financial
instrument, type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
|
b) |
Nature of the transaction |
Other transaction (acquisition of shares in
accordance with the recruitment package)
|
|
c) |
Price(s) and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
|
DKK 0.00 |
3,025 shares |
|
|
|
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price
|
3,025 shares
DKK 0.00
|
|
e) |
Date of the transaction |
2021-02-08 |
|
f) |
Place of the transaction |
Outside a trading venue |
Definitions and background information:
Publication
Publication shall take place no later than three working days after
the trading by board members, executives or their associated
persons. Publication is only required when the total amount of
transactions of a specific board member/executive or his/her
associated persons in any one calendar year has reached EUR 20,000
(calculated individually).
Who are board members, executives and associated
persons?
Board members and executives are members of the Board
of Directors and Executive Management, respectively, of Novo
Nordisk A/S. Associated persons are defined as the following
persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) Other
relatives defined as brothers, sisters, parents, grandparents,
children, grandchildren, cousins etc. who have shared the same
household with a board member or executive for a period of at least
one year on the date of the given transaction and 4) any legal
persons, trust, or partnership, the managerial responsibilities of
which are discharged by a board member/executive or by a person
referred to in items 1)-3) above, or which is directly or
indirectly controlled by such a person, or which is set up for the
benefit of such a person, or the economic interests of which are
substantially equivalent to those of such a person.
What is trading/transaction?
Trading is any kind of transaction, including shares and share
related securities purchased or otherwise acquired, sold or
otherwise disposed, gifts, mortgages, heritage and grants,
allotments and exercise of options.
Page 3 of 3
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and aggregated
information?
The volume of transaction is the number of shares (of DKK 0.20
nominal value) or other financial instruments traded. In case of a
single transaction the price is the price of that single
transaction. In case of multiple transactions, when the
transactions relate to the same financial instrument, are of the
same nature, are executed on the same day and are executed on the
same place, the volume must be aggregated. The price of the
aggregated transactions is the weighted average price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
|
Media: |
|
|
| Mette Kruse Danielsen |
+45 4442 3883 |
mkd@novonordisk.com |
| Michael Bachner (US) |
+1 609 664 7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Valdemar Borum Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| Mark Joseph Root |
+45 3079 4211 |
mjhr@novonordisk.com |
| Kristoffer Due Berg (US) |
+1 609 235 2989 |
krdb@novonordisk.com |
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
| |
|
Company announcement No 9 / 2021 |
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
| Date: February
10, 2021 |
NOVO
NORDISK A/S
Lars Fruergaard Jørgensen
Chief
Executive Officer
|
